EVALUATION OF THE ECONOMIC IMPACT OF THE LOSS OF EXPENSIVE DRUGS IN THE RETROCESSION UNIT OF THE HMIMV OF RABAT

Hajar Zhar*, Yassine Atbib, Aboubacar Sékou KABA, Youssef Moutaouakkil, Yasmina Tadlaoui, Yassir Bousliman

ABSTRACT

Introduction: The unit of retrocession of anticancer drugs at the Military Hospital of Instruction Mohammed V (HMIMV) Rabat ensures the dispensation of anticancer chemotherapy drugs to patients. The objective of this study is to quantify the losses of leftovers generated by the current mode of preparation of anticancer chemotherapies for our hospital establishment. Materials and Methods: This is a retrospective study that was conducted at the cancer drug retrocession unit of HMIMV in Rabat, Morocco between January and October 2020. The main analysis compared the actual cost of leftover preparations with the theoretical costs of leftover preparations if they were made in the care units. This analysis covered a set of 3000 chemotherapy preparations prescribed in the prescriptions. Results: During the 10 months of the study, 4,511 vials of the different molecules in the study were dispensed to patients, corresponding to a total of €480,518.07. From this number of vials used, we can save 1,779 vials per medical prescription, which represents an average of potential savings of around €56,572.50 (total cost of the remaining vials for 10 months*100/total amount of the expenses) This amount corresponds to 11.77% of the total amount of care granted to patients. The total cost of the remainders for 10 months is 56,572.50 euros, which corresponds to a total annual cost of 67,887.00 euros. TRASTUSUMAB, BEVACIZUMAB, BOTEZOMIB, AZACITIDINE, CETUXIMAB and PEMETREXED are the six molecules that represent the most losses among all our molecules studied. Conclusion: According to the financial elements found in our study, it is imperative to set up a centralized cytotoxic reconstitution unit (CCRU). The management of leftovers in this unit can generate significant savings depending on the molecules. Centralizing the preparation of anti-cancer drugs is of economic interest, by optimizing the management of leftovers. Our perspective is to be able to participate in this new setting up of the UCRC and to compare our results with those of the new installation.

Keywords: Retrocession, anti-cancer drugs, expensive drugs, loss, leftovers.